First human trial launches for brain cancer vaccine
NCT ID NCT07422896
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new personalized vaccine called Bvax, made from each patient's own cells, combined with standard chemoradiation for newly diagnosed glioblastoma. The study will enroll 25 people to check safety and see if the vaccine helps control the cancer. It is the first time this approach is tested in humans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
B-cell vaccine (Bvax) plus autologous CD8 T cells
What this could lead to
If successful, this could point toward a new way to harness the immune system against glioblastoma, potentially improving survival when added to standard treatment.
What could go wrong
This is a very early, first-in-human trial with only 25 participants, so safety and effectiveness are not yet known. The vaccine is personalized and complex, which may limit scalability.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact